Page 1 - Immunology_1_2022
P. 1


                                                     ISSUE 1 2022

                                                                                AS-NEEDED ANTI-INFLAMMATORY
                                                                                RELIEVER WITH OR WITHOUT
                                                                                MAINTENANCE    1

                                                                                Now a preferred anti-inflammatory reliever in
                                                                                mild asthma, as well as in moderate-to-severe

                                                                                asthma patientsprescribed maintenance and
       GINA RECOMMENDS ICS-FORMOTEROL, NOW                                      reliever therapy 1
       FOR ANY ASTHMA SEVERITY*, TO ACHIEVE                                                               AS
       OF ASTHMA ATTACKS   1                                                                        EASY

                 A preferred reliever that WORKS AS FAST AS SABA
                 to relieve symptoms 1,2,3,4                                                              AS
        3        SUPERIOR IN REDUCING EXACERBATIONS,                                           TWIST,
                 vs SABA + ICS-LABA maintenance
         1       ONLY ONE INHALER that keeps life simple and  3,4,8           TWIST     1      CLICK,

                 uses a patient’s natural relief-seeking behaviour
                                                                                            INHALE               3,4

       * Moderate to severe asthma on top of maintenance
       SABA: short-acting beta2-agonist; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist
       References: 1. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2021. [cited 2021 September 10]; Available from: 2. Seberova E , Andersson A. Oxis®(formoterol given by Turbuhaler® ) showed as rapid an onset
       of action as salbutamol given by a pMDI. Respir Med 2000;94(6):607-611. 3. Symbicord® Turbuhaler® 80:4,5 and 160:4,5 Inhaler Approved Package Insert, July 2021. 4. Symbicord® Turbuhaler® 320:9 Inhaler Approved Package Insert, September 2012. 5. Rabe KF, Atienza T,
       Magyar P, et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006;368:744-753. 6. Vogelmeier C, D’Urzo A, Pauwels R, et al. Budesonide/formoterol maintenance and reliever
       therapy: an effective asthma treatment option? Eur Respir J 2005;26:819-828. 7. Bousquet J, Boulet LP, Peters MJ, et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med 2007;101:2437-2446. 8. Kuna P,
       Peters MJ, Manjra AI, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007;61(5):725 -736.
       S4 Symbicord® Turbuhaler® 80:4,5 μg/dose & 160:4,5 μg/dose (Inhaler). Reg. No. 35/21.5.1/0404;35/21.5.1/0405. Each delivered dose contains as active constituents: budesonide 80 micrograms and formoterol fumarate dihydrate 4,5 micrograms; or budesonide
       160 micrograms and formoterol fumarate dihydrate 4,5 micrograms, respectively. Contains sugar. PHARMACOLOGICAL CLASSIFICATION: A 21.5.1 Corticosteroids and analogues. INDICATIONS: Asthma: SYMBICORD TURBUHALER 80:4,5 is indicated in the treatment of asthma in
       adolescents and adults where use of a combination (inhaled corticosteroid and long-acting beta-2-agonist) is appropriate. SYMBICORD TURBUHALER 160:4,5 μg/dose is indicated in the treatment of asthma in adolescents and adults to achieve overall asthma control, including the
       prevention and relief of symptoms as well as the reduction of the risk of exacerbations. COPD: SYMBICORD TURBUHALER 160:4,5 μg/dose is indicated in the regular treatment of patients with moderate to severe chronic
       obstructive pulmonary disease (COPD), with frequent symptoms and a history of exacerbations. For full prescribing information, kindly refer to the approved package insert.
       AstraZeneca Pharmaceuticals (Pty) Ltd. Reg. No. 1992/005854/07. Building 2, Northdowns Office Park, 17 Georgian Crescent West, Bryanston, 2191. Private Bag X23, Bryanston, 2021. Tel: 011 797-6000. Fax: 011 797-6001. Symbicord and Turbuhaler are registered trademarks of the AstraZeneca group of companies. Expiry Date: October 2023. Activity ID: ZA-3218
   1   2   3   4   5   6